The prognosis is dismal for childhood, adolescent, and young adult (CAYA) relapsed and/or refractory (R/R) non-Hodgkin lymphoma (NHL) with 2-year overall survival (OS) less than 25% in many cases [[1], [2], [3]]. The addition of antibody therapy to chemotherapy in the treatment of B-cell Non-Hodgkin Lymphoma (B-NHL) in CAYA has significantly improved the outcome in these patients [[4], [5], [6]]. A variety of cellular immunotherapies has been investigated and provide alternative options for CAYA patients with R/R NHL. These cellular therapies include but not limited to autologous/allogeneic stem cell transplant (SCT), viral activated cytotoxic T-lymphocyte (CTL), chimeric antigen receptor (CAR) T-cells, natural killer (NK) and CAR NK cells, the combination of T-cells with bispecific T-cell engager, the combination of NK/CAR NK-cells with novel antibodies and immunomodulators (Fig. 1) [2]. Here, we provide an update on the advances in monoclonal antibodies, antibody drug conjugates, bispecific and trispecific engagers, and some of the cellular immunotherapies in CAYA with mature B-cell NHL.